6 O
ADVERSE O
REACTIONS O
The O
following O
serious O
and O
otherwise O
important O
adverse O
drug O
reactions O
are O
discussed O
in O
greater O
detail O
in O
other O
sections O
of O
labeling O
: O
* O
Lymphoma B-OSE_Labeled_AE
and O
Other O
Malignancies B-OSE_Labeled_AE
[ O
see O
Boxed O
Warning O
, O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
* O
Serious O
Infections B-OSE_Labeled_AE
[ O
see O
Boxed O
Warning O
, O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
* O
Polyoma B-OSE_Labeled_AE
Virus I-OSE_Labeled_AE
Infections I-OSE_Labeled_AE
[ O
see O
Boxed O
Warning O
, O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
* O
CMV B-OSE_Labeled_AE
Infections I-OSE_Labeled_AE
[ O
see O
Boxed O
Warning O
, O
Warnings O
and O
Precautions O
( O
5.5 O
) O
] O
* O
New O
Onset O
Diabetes B-OSE_Labeled_AE
After O
Transplant O
[ O
see O
Warnings O
and O
Precautions O
( O
5.6 O
) O
] O
* O
Nephrotoxicity B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.7 O
) O
] O
* O
Neurotoxicity B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.8 O
) O
] O
* O
Hyperkalemia B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.9 O
) O
] O
* O
Hypertension B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.10 O
) O
] O
* O
Anaphylaxis B-OSE_Labeled_AE
with O
Prograf O
Injection O
[ O
see O
Warnings O
and O
Precautions O
( O
5.11 O
) O
] O
* O
Myocardial B-OSE_Labeled_AE
Hypertrophy I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.15 O
) O
] O
* O
Pure B-OSE_Labeled_AE
Red I-OSE_Labeled_AE
Cell I-OSE_Labeled_AE
Aplasia I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.17 O
) O
] O
* O
Gastrointestinal B-OSE_Labeled_AE
Perforation I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.18 O
) O
] O
* O
Kidney B-Not_AE_Candidate
Transplant I-Not_AE_Candidate
: O
The O
most O
common O
adverse O
reactions O
( O
> O
= O
30 O
% O
) O
were O
infection B-OSE_Labeled_AE
, O
tremor B-OSE_Labeled_AE
, O
hypertension B-OSE_Labeled_AE
, O
abnormal B-OSE_Labeled_AE
renal I-OSE_Labeled_AE
function I-OSE_Labeled_AE
, O
constipation B-OSE_Labeled_AE
, O
diarrhea B-OSE_Labeled_AE
, O
headache B-OSE_Labeled_AE
, O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
insomnia B-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
hypomagnesemia B-OSE_Labeled_AE
, O
urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
hypophosphatemia B-OSE_Labeled_AE
, O
peripheral B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
, O
asthenia B-OSE_Labeled_AE
, O
pain B-OSE_Labeled_AE
, O
hyperlipidemia B-OSE_Labeled_AE
, O
hyperkalemia B-OSE_Labeled_AE
, O
anemia B-OSE_Labeled_AE
( O
6.1 O
) O
* O
Liver B-Not_AE_Candidate
Transplant I-Not_AE_Candidate
: O
The O
most O
common O
adverse O
reactions O
( O
> O
= O
40 O
% O
) O
were O
tremor B-OSE_Labeled_AE
, O
headache B-OSE_Labeled_AE
, O
diarrhea B-OSE_Labeled_AE
, O
hypertension B-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
abnormal B-OSE_Labeled_AE
renal I-OSE_Labeled_AE
function I-OSE_Labeled_AE
, O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
insomnia B-OSE_Labeled_AE
, O
paresthesia B-OSE_Labeled_AE
, O
anemia B-OSE_Labeled_AE
, O
pain B-OSE_Labeled_AE
, O
fever B-OSE_Labeled_AE
, O
asthenia B-OSE_Labeled_AE
, O
hyperkalemia B-OSE_Labeled_AE
, O
hypomagnesemia B-OSE_Labeled_AE
, O
and O
hyperglycemia B-OSE_Labeled_AE
( O
6.1 O
) O
* O
Heart B-Not_AE_Candidate
Transplant I-Not_AE_Candidate
: O
The O
most O
common O
adverse O
reactions O
( O
> O
= O
15 O
% O
) O
were O
abnormal B-OSE_Labeled_AE
renal I-OSE_Labeled_AE
function I-OSE_Labeled_AE
, O
hypertension B-OSE_Labeled_AE
, O
diabetes B-OSE_Labeled_AE
mellitus I-OSE_Labeled_AE
, O
CMV B-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
tremor B-OSE_Labeled_AE
, O
hyperglycemia B-OSE_Labeled_AE
, O
leukopenia B-OSE_Labeled_AE
, O
infection B-OSE_Labeled_AE
, O
anemia B-OSE_Labeled_AE
, O
bronchitis B-OSE_Labeled_AE
, O
pericardial B-OSE_Labeled_AE
effusion I-OSE_Labeled_AE
, O
urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
and O
hyperlipemia B-OSE_Labeled_AE
( O
6.1 O
) O
EXCERPT O
: O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Astellas O
Pharma O
US O
, O
Inc O
at O
1-800-727-7003 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Studies O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

In O
addition O
, O
the O
clinical O
trials O
were O
not O
designed O
to O
establish O
comparative O
differences O
across O
study O
arms O
with O
regards O
to O
the O
adverse O
reactions O
discussed O
below O
. O

Kidney O
Transplant O
The O
incidence O
of O
adverse O
reactions O
was O
determined O
in O
three O
randomized O
kidney B-Not_AE_Candidate
transplant I-Not_AE_Candidate
trials O
. O

One O
of O
the O
trials O
used O
azathioprine O
( O
AZA O
) O
and O
corticosteroids O
and O
two O
of O
the O
trials O
used O
mycophenolate O
mofetil O
( O
MMF O
) O
and O
corticosteroids O
concomitantly O
for O
maintenance O
immunosuppression B-NonOSE_AE
. O

Prograf-based O
immunosuppression B-NonOSE_AE
in O
conjunction O
with O
azathioprine O
and O
corticosteroids O
following O
kidney B-Not_AE_Candidate
transplantation I-Not_AE_Candidate
was O
assessed O
in O
trial O
where O
205 O
patients O
received O
Prograf O
based O
immunosuppression B-NonOSE_AE
and O
207 O
patients O
received O
cyclosporine O
based O
immunosuppression B-NonOSE_AE
. O

The O
trial O
population O
had O
a O
mean O
age O
of O
43 O
years O
( O
mean+/-sd O
was O
43+/-13 O
years O
on O
Prograf O
and O
44+/-12 O
years O
on O
cyclosporine O
arm O
) O
, O
the O
distribution O
was O
61 O
% O
male O
, O
and O
the O
composition O
was O
White O
( O
58 O
% O
) O
, O
Black O
( O
25 O
% O
) O
, O
Hispanic O
( O
12 O
% O
) O
and O
Other O
( O
5 O
% O
) O
. O

The O
12 O
month O
post B-NonOSE_AE
- I-NonOSE_AE
transplant I-NonOSE_AE
information O
from O
this O
trial O
is O
presented O
below O
. O

The O
most O
common O
adverse O
reactions O
( O
> O
= O
30 O
% O
) O
observed O
in O
Prograf-treated O
kidney B-Not_AE_Candidate
transplant I-Not_AE_Candidate
patients O
are O
: O
infection B-OSE_Labeled_AE
, O
tremor B-OSE_Labeled_AE
, O
hypertension B-OSE_Labeled_AE
, O
abnormal B-OSE_Labeled_AE
renal I-OSE_Labeled_AE
function I-OSE_Labeled_AE
, O
constipation B-OSE_Labeled_AE
, O
diarrhea B-OSE_Labeled_AE
, O
headache B-OSE_Labeled_AE
, O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
insomnia B-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
hypomagnesemia B-OSE_Labeled_AE
, O
urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
hypophosphatemia B-OSE_Labeled_AE
, O
peripheral B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
, O
asthenia B-OSE_Labeled_AE
, O
pain B-OSE_Labeled_AE
, O
hyperlipidemia B-OSE_Labeled_AE
, O
hyperkalemia B-OSE_Labeled_AE
and O
anemia B-OSE_Labeled_AE
. O

Adverse O
reactions O
that O
occurred O
in O
> O
= O
15 O
% O
of O
kidney B-Not_AE_Candidate
transplant I-Not_AE_Candidate
patients O
treated O
with O
Prograf O
in O
conjunction O
with O
azathioprine O
are O
presented O
below O
: O
Table O
4 O
. O

Kidney O
Transplantation O
: O
Adverse O
Reactions O
Occurring O
in O
> O
= O
15 O
% O
of O
Patients O
Treated O
with O
Prograf O
in O
Conjunction O
with O
Azathioprine O
( O
AZA O
) O
Prograf/AZA O
( O
N=205 O
) O
Cyclosporine/AZA O
( O
N=207 O
) O
Nervous B-NonOSE_AE
System I-NonOSE_AE
Tremor B-OSE_Labeled_AE
Headache B-OSE_Labeled_AE
Insomnia B-OSE_Labeled_AE
Paresthesia B-OSE_Labeled_AE
Dizziness B-OSE_Labeled_AE
54 O
% O
44 O
% O
32 O
% O
23 O
% O
19 O
% O
34 O
% O
38 O
% O
30 O
% O
16 O
% O
16 O
% O
Gastrointestinal B-NonOSE_AE
Diarrhea B-OSE_Labeled_AE
Nausea B-OSE_Labeled_AE
Constipation B-OSE_Labeled_AE
Vomiting B-OSE_Labeled_AE
Dyspepsia B-OSE_Labeled_AE
44 O
% O
38 O
% O
35 O
% O
29 O
% O
28 O
% O
41 O
% O
36 O
% O
43 O
% O
23 O
% O
20 O
% O
Cardiovascular B-NonOSE_AE
Hypertension B-OSE_Labeled_AE
Chest B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
50 O
% O
19 O
% O
52 O
% O
13 O
% O
Urogenital B-NonOSE_AE
Creatinine B-OSE_Labeled_AE
Increased I-OSE_Labeled_AE
Urinary B-OSE_Labeled_AE
Tract I-OSE_Labeled_AE
Infection I-OSE_Labeled_AE
45 O
% O
34 O
% O
42 O
% O
35 O
% O
Metabolic B-NonOSE_AE
and I-NonOSE_AE
Nutritional I-NonOSE_AE
Hypophosphatemia B-OSE_Labeled_AE
Hypomagnesemia B-OSE_Labeled_AE
Hyperlipemia B-OSE_Labeled_AE
Hyperkalemia B-OSE_Labeled_AE
Diabetes B-OSE_Labeled_AE
Mellitus I-OSE_Labeled_AE
Hypokalemia B-OSE_Labeled_AE
Hyperglycemia B-OSE_Labeled_AE
Edema B-OSE_Labeled_AE
49 O
% O
34 O
% O
31 O
% O
31 O
% O
24 O
% O
22 O
% O
22 O
% O
18 O
% O
53 O
% O
17 O
% O
38 O
% O
32 O
% O
9 O
% O
25 O
% O
16 O
% O
19 O
% O
Hemic B-NonOSE_AE
and I-NonOSE_AE
Lymphatic I-NonOSE_AE
Anemia B-OSE_Labeled_AE
Leukopenia B-OSE_Labeled_AE
30 O
% O
15 O
% O
24 O
% O
17 O
% O
Miscellaneous B-NonOSE_AE
Infection B-OSE_Labeled_AE
Peripheral B-OSE_Labeled_AE
Edema I-OSE_Labeled_AE
Asthenia B-OSE_Labeled_AE
Abdominal B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
Pain B-OSE_Labeled_AE
Fever B-OSE_Labeled_AE
Back B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
45 O
% O
36 O
% O
34 O
% O
33 O
% O
32 O
% O
29 O
% O
24 O
% O
49 O
% O
48 O
% O
30 O
% O
31 O
% O
30 O
% O
29 O
% O
20 O
% O
Respiratory B-NonOSE_AE
System I-NonOSE_AE
Dyspnea B-OSE_Labeled_AE
Cough B-OSE_Labeled_AE
Increased I-OSE_Labeled_AE
22 O
% O
18 O
% O
18 O
% O
15 O
% O
Musculoskeletal B-NonOSE_AE
Arthralgia B-OSE_Labeled_AE
25 O
% O
24 O
% O
Skin B-NonOSE_AE
Rash B-OSE_Labeled_AE
Pruritus B-OSE_Labeled_AE
17 O
% O
15 O
% O
12 O
% O
7 O
% O
Two O
trials O
were O
conducted O
for O
Prograf-based O
immunosuppression B-NonOSE_AE
in O
conjunction O
with O
MMF O
and O
corticosteroids O
. O

In O
the O
non-US O
trial O
( O
Study O
1 O
) O
, O
the O
incidence O
of O
adverse O
reactions O
was O
based O
on O
1195 O
kidney B-Not_AE_Candidate
transplant I-Not_AE_Candidate
patients O
that O
received O
Prograf O
( O
Group O
C O
, O
n=403 O
) O
, O
or O
one O
of O
two O
cyclosporine O
( O
CsA O
) O
regimens O
( O
Group O
A O
, O
n=384 O
and O
Group O
B O
, O
n=408 O
) O
in O
combination O
with O
MMF O
and O
corticosteroids O
; O
all O
patients O
, O
except O
those O
in O
one O
of O
the O
two O
cyclosporine O
groups O
, O
also O
received O
induction O
with O
daclizumab O
. O

The O
trial O
population O
had O
a O
mean O
age O
of O
46 O
years O
( O
range O
17 O
to O
76 O
) O
, O
the O
distribution O
was O
65 O
% O
male O
, O
and O
the O
composition O
was O
93 O
% O
Caucasian O
. O

The O
12 O
month O
post-transplant O
information O
from O
this O
trial O
is O
presented O
below O
. O

Adverse O
reactions O
that O
occurred O
in O
> O
= O
10 O
% O
of O
kidney B-Not_AE_Candidate
transplant I-Not_AE_Candidate
patients O
treated O
with O
Prograf O
in O
conjunction O
with O
MMF O
in O
Study O
1 O
[ O
Note O
: O
This O
trial O
was O
conducted O
entirely O
outside O
of O
the O
United O
States O
. O

Such O
trials O
often O
report O
a O
lower O
incidence O
of O
adverse O
reactions O
in O
comparison O
to O
U.S O
. O
trials O
] O
are O
presented O
below O
: O
Table O
5 O
. O

Kidney O
Transplantation O
: O
Adverse O
Reactions O
Occurring O
in O
> O
= O
10 O
% O
of O
Patients O
Treated O
with O
Prograf O
in O
Conjunction O
with O
MMF O
( O
Study O
1 O
) O
Key O
: O
Group O
A O
= O
CsA/MMF/CS O
, O
B O
= O
CsA/MMF/CS/Daclizumab O
, O
C= O
Tac/MMF/CS/DaclizumabCsA= O
Cyclosporine O
, O
CS O
= O
Corticosteroids O
, O
Tac O
= O
Tacrolimus O
, O
MMF O
= O
mycophenolate O
mofetil O
Prograf O
( O
Group O
C O
) O
Cyclosporine O
( O
Group O
A O
) O
Cyclosporine O
( O
Group O
B O
) O
( O
N=403 O
) O
( O
N=384 O
) O
( O
N=408 O
) O
Diarrhea B-OSE_Labeled_AE
25 O
% O
16 O
% O
13 O
% O
Urinary B-OSE_Labeled_AE
Tract I-OSE_Labeled_AE
Infection I-OSE_Labeled_AE
24 O
% O
28 O
% O
24 O
% O
Anemia B-OSE_Labeled_AE
17 O
% O
19 O
% O
17 O
% O
Hypertension B-OSE_Labeled_AE
13 O
% O
14 O
% O
12 O
% O
Leukopenia B-OSE_Labeled_AE
13 O
% O
10 O
% O
10 O
% O
Edema B-OSE_Labeled_AE
Peripheral I-OSE_Labeled_AE
11 O
% O
12 O
% O
13 O
% O
Hyperlipidemia B-OSE_Labeled_AE
10 O
% O
15 O
% O
13 O
% O
In O
the O
U.S O
. O
trial O
( O
Study O
2 O
) O
with O
Prograf-based O
immunosuppression B-NonOSE_AE
in O
conjunction O
with O
MMF O
and O
corticosteroids O
, O
424 O
kidney B-Not_AE_Candidate
transplant I-Not_AE_Candidate
patients O
received O
Prograf O
( O
n=212 O
) O
or O
cyclosporine O
( O
n=212 O
) O
in O
combination O
with O
MMF O
1 O
gram O
twice O
daily O
, O
basiliximab O
induction O
, O
and O
corticosteroids O
. O

The O
trial O
population O
had O
a O
mean O
age O
of O
48 O
years O
( O
range O
17 O
to O
77 O
) O
, O
the O
distribution O
was O
63 O
% O
male O
, O
and O
the O
composition O
was O
White O
( O
74 O
% O
) O
, O
Black O
( O
20 O
% O
) O
, O
Asian O
( O
3 O
% O
) O
and O
other O
( O
3 O
% O
) O
. O

The O
12 O
month O
post B-NonOSE_AE
- I-NonOSE_AE
transplant I-NonOSE_AE
information O
from O
this O
trial O
is O
presented O
below O
. O

Adverse O
reactions O
that O
occurred O
in O
> O
=15 O
% O
of O
kidney B-Not_AE_Candidate
transplant I-Not_AE_Candidate
patients O
treated O
with O
Prograf O
in O
conjunction O
with O
MMF O
in O
Study O
2 O
are O
presented O
below O
: O
Table O
6 O
. O

Kidney O
Transplantation O
: O
Adverse O
Reactions O
Occurring O
in O
> O
= O
15 O
% O
of O
Patients O
Treated O
with O
Prograf O
in O
Conjunction O
with O
MMF O
( O
Study O
2 O
) O
Prograf/MMF O
Cyclosporine/MMF O
( O
N=212 O
) O
( O
N=212 O
) O
Gastrointestinal B-NonOSE_AE
Disorders I-NonOSE_AE
Diarrhea B-OSE_Labeled_AE
44 O
% O
26 O
% O
Nausea B-OSE_Labeled_AE
39 O
% O
47 O
% O
Constipation B-OSE_Labeled_AE
36 O
% O
41 O
% O
Vomiting B-OSE_Labeled_AE
26 O
% O
25 O
% O
Dyspepsia B-OSE_Labeled_AE
18 O
% O
15 O
% O
Injury B-NonOSE_AE
, I-NonOSE_AE
Poisoning I-NonOSE_AE
, I-NonOSE_AE
and I-NonOSE_AE
Procedural I-NonOSE_AE
Complications I-NonOSE_AE
Post B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Procedural I-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
29 O
% O
27 O
% O
Incision B-OSE_Labeled_AE
Site I-OSE_Labeled_AE
Complication I-OSE_Labeled_AE
28 O
% O
23 O
% O
Graft B-OSE_Labeled_AE
Dysfunction I-OSE_Labeled_AE
24 O
% O
18 O
% O
Metabolism B-NonOSE_AE
and I-NonOSE_AE
Nutrition I-NonOSE_AE
Disorders I-NonOSE_AE
Hypomagnesemia B-OSE_Labeled_AE
28 O
% O
22 O
% O
Hypophosphatemia B-OSE_Labeled_AE
28 O
% O
21 O
% O
Hyperkalemia B-OSE_Labeled_AE
26 O
% O
19 O
% O
Hyperglycemia B-OSE_Labeled_AE
21 O
% O
15 O
% O
Hyperlipidemia B-OSE_Labeled_AE
18 O
% O
25 O
% O
Hypokalemia B-OSE_Labeled_AE
16 O
% O
18 O
% O
Nervous B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
Tremor B-OSE_Labeled_AE
34 O
% O
20 O
% O
Headache B-OSE_Labeled_AE
24 O
% O
25 O
% O
Blood B-NonOSE_AE
and I-NonOSE_AE
Lymphatic I-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
Anemia B-OSE_Labeled_AE
30 O
% O
28 O
% O
Leukopenia B-OSE_Labeled_AE
16 O
% O
12 O
% O
Miscellaneous B-NonOSE_AE
Edema B-OSE_Labeled_AE
Peripheral I-OSE_Labeled_AE
35 O
% O
46 O
% O
Hypertension B-OSE_Labeled_AE
32 O
% O
35 O
% O
Insomnia B-OSE_Labeled_AE
30 O
% O
21 O
% O
Urinary B-OSE_Labeled_AE
Tract I-OSE_Labeled_AE
Infection I-OSE_Labeled_AE
26 O
% O
22 O
% O
Blood B-OSE_Labeled_AE
Creatinine I-OSE_Labeled_AE
Increased I-OSE_Labeled_AE
23 O
% O
23 O
% O
Less O
frequently O
observed O
adverse O
reactions O
in O
both O
liver B-Not_AE_Candidate
transplantation I-Not_AE_Candidate
and O
kidney B-Not_AE_Candidate
transplantation I-Not_AE_Candidate
patients O
are O
described O
under O
the O
subsection O
Less O
Frequently O
Reported O
Adverse O
Reactions O
. O

Liver O
Transplantation O
There O
were O
two O
randomized O
comparative O
liver B-Not_AE_Candidate
transplant I-Not_AE_Candidate
trials O
. O

In O
the O
U.S O
. O
trial O
, O
263 O
adult O
and O
pediatric O
patients O
received O
tacrolimus O
and O
steroids O
and O
266 O
patients O
received O
cyclosporine-based O
immunosuppressive O
regimen O
( O
CsA/AZA O
) O
. O

The O
trial O
population O
had O
a O
mean O
age O
of O
44 O
years O
( O
range O
0.4 O
to70 O
) O
, O
the O
distribution O
was O
52 O
% O
male O
, O
and O
the O
composition O
was O
White O
( O
78 O
% O
) O
, O
Black O
( O
5 O
% O
) O
, O
Asian O
( O
2 O
% O
) O
, O
Hispanic O
( O
13 O
% O
) O
and O
Other O
( O
2 O
% O
) O
. O

In O
the O
European O
trial O
, O
270 O
patients O
received O
tacrolimus O
and O
steroids O
and O
275 O
patients O
received O
CsA/AZA O
. O

The O
trial O
population O
had O
a O
mean O
age O
of O
46 O
years O
( O
range O
15 O
to O
68 O
) O
, O
the O
distribution O
was O
59 O
% O
male O
, O
and O
the O
composition O
was O
White O
( O
95.4 O
% O
) O
, O
Black O
( O
1 O
% O
) O
, O
Asian O
( O
2 O
% O
) O
and O
Other O
( O
2 O
% O
) O
. O

The O
proportion O
of O
patients O
reporting O
more O
than O
one O
adverse O
event O
was O
> O
99 O
% O
in O
both O
the O
tacrolimus O
group O
and O
the O
CsA/AZA O
group O
. O

Precautions O
must O
be O
taken O
when O
comparing O
the O
incidence O
of O
adverse O
reactions O
in O
the O
U.S O
. O
trial O
to O
that O
in O
the O
European O
trial O
. O

The O
12-month O
post-transplant O
information O
from O
the O
U.S O
. O
trial O
and O
from O
the O
European O
trial O
is O
presented O
below O
. O

The O
two O
trials O
also O
included O
different O
patient O
populations O
and O
patients O
were O
treated O
with O
immunosuppressive O
regimens O
of O
differing O
intensities O
. O

Adverse O
reactions O
reported O
in O
> O
=15 O
% O
in O
tacrolimus O
patients O
( O
combined O
trial O
results O
) O
are O
presented O
below O
for O
the O
two O
controlled O
trials O
in O
liver B-Not_AE_Candidate
transplantation I-Not_AE_Candidate
. O

The O
most O
common O
adverse O
reactions O
( O
> O
= O
40 O
% O
) O
observed O
in O
Prograf-treated O
liver B-Not_AE_Candidate
transplant I-Not_AE_Candidate
patients O
are O
: O
tremor B-OSE_Labeled_AE
, O
headache B-OSE_Labeled_AE
, O
diarrhea B-OSE_Labeled_AE
, O
hypertension B-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
abnormal B-OSE_Labeled_AE
renal I-OSE_Labeled_AE
function I-OSE_Labeled_AE
, O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
insomnia B-OSE_Labeled_AE
, O
paresthesia B-OSE_Labeled_AE
, O
anemia B-OSE_Labeled_AE
, O
pain B-OSE_Labeled_AE
, O
fever B-OSE_Labeled_AE
, O
asthenia B-OSE_Labeled_AE
, O
hyperkalemia B-OSE_Labeled_AE
, O
hypomagnesemia B-OSE_Labeled_AE
, O
and O
hyperglycemia B-OSE_Labeled_AE
. O

These O
all O
occur O
with O
oral O
and O
IV O
administration O
of O
Prograf O
and O
some O
may O
respond O
to O
a O
reduction O
in O
dosing O
( O
e.g. O
, O
tremor B-OSE_Labeled_AE
, O
headache B-OSE_Labeled_AE
, O
paresthesia B-OSE_Labeled_AE
, O
hypertension B-OSE_Labeled_AE
) O
. O

Diarrhea B-OSE_Labeled_AE
was O
sometimes O
associated O
with O
other O
gastrointestinal B-OSE_Labeled_AE
complaints I-OSE_Labeled_AE
such O
as O
nausea B-OSE_Labeled_AE
and O
vomiting B-OSE_Labeled_AE
. O

Table O
7 O
. O

Liver O
Transplantation O
: O
Adverse O
Reactions O
Occurring O
in O
> O
= O
15 O
% O
of O
Patients O
Treated O
with O
Prograf O
U.S O
. O
TRIAL O
EUROPEAN O
TRIAL O
Prograf O
( O
N=250 O
) O
Cyclosporine/AZA O
( O
N=250 O
) O
Prograf O
( O
N=264 O
) O
Cyclosporine/AZA O
( O
N=265 O
) O
Nervous B-NonOSE_AE
System I-NonOSE_AE
Headache B-OSE_Labeled_AE
Insomnia B-OSE_Labeled_AE
Tremor B-OSE_Labeled_AE
Paresthesia B-OSE_Labeled_AE
64 O
% O
64 O
% O
56 O
% O
40 O
% O
60 O
% O
68 O
% O
46 O
% O
30 O
% O
37 O
% O
32 O
% O
48 O
% O
17 O
% O
26 O
% O
23 O
% O
32 O
% O
17 O
% O
Gastrointestinal B-NonOSE_AE
Diarrhea B-OSE_Labeled_AE
Nausea B-OSE_Labeled_AE
LFT B-OSE_Labeled_AE
Abnormal I-OSE_Labeled_AE
Anorexia B-OSE_Labeled_AE
Vomiting B-OSE_Labeled_AE
Constipation B-OSE_Labeled_AE
72 O
% O
46 O
% O
36 O
% O
34 O
% O
27 O
% O
24 O
% O
47 O
% O
37 O
% O
30 O
% O
24 O
% O
15 O
% O
27 O
% O
37 O
% O
32 O
% O
6 O
% O
7 O
% O
14 O
% O
23 O
% O
27 O
% O
27 O
% O
5 O
% O
5 O
% O
11 O
% O
21 O
% O
Cardiovascular B-NonOSE_AE
Hypertension B-OSE_Labeled_AE
47 O
% O
56 O
% O
38 O
% O
43 O
% O
Urogenital B-NonOSE_AE
Kidney B-OSE_Labeled_AE
Function I-OSE_Labeled_AE
Abnormal I-OSE_Labeled_AE
40 O
% O
27 O
% O
36 O
% O
23 O
% O
Creatinine B-OSE_Labeled_AE
Increased I-OSE_Labeled_AE
39 O
% O
25 O
% O
24 O
% O
19 O
% O
BUN B-OSE_Labeled_AE
Increased I-OSE_Labeled_AE
30 O
% O
22 O
% O
12 O
% O
9 O
% O
Oliguria B-OSE_Labeled_AE
18 O
% O
15 O
% O
19 O
% O
12 O
% O
Urinary B-OSE_Labeled_AE
Tract I-OSE_Labeled_AE
Infection I-OSE_Labeled_AE
16 O
% O
18 O
% O
21 O
% O
19 O
% O
Metabolic B-NonOSE_AE
and I-NonOSE_AE
Nutritional I-NonOSE_AE
Hypomagnesemia B-OSE_Labeled_AE
Hyperglycemia B-OSE_Labeled_AE
Hyperkalemia B-OSE_Labeled_AE
Hypokalemia B-OSE_Labeled_AE
48 O
% O
47 O
% O
45 O
% O
29 O
% O
45 O
% O
38 O
% O
26 O
% O
34 O
% O
16 O
% O
33 O
% O
13 O
% O
13 O
% O
9 O
% O
22 O
% O
9 O
% O
16 O
% O
Hemic B-NonOSE_AE
and I-NonOSE_AE
Lymphatic I-NonOSE_AE
Anemia B-OSE_Labeled_AE
Leukocytosis B-OSE_Labeled_AE
Thrombocytopenia B-OSE_Labeled_AE
47 O
% O
32 O
% O
24 O
% O
38 O
% O
26 O
% O
20 O
% O
5 O
% O
8 O
% O
14 O
% O
1 O
% O
8 O
% O
19 O
% O
Miscellaneous B-NonOSE_AE
Pain B-OSE_Labeled_AE
Abdominal B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
Asthenia B-OSE_Labeled_AE
Fever B-OSE_Labeled_AE
Back B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
Ascites B-OSE_Labeled_AE
Peripheral B-OSE_Labeled_AE
Edema I-OSE_Labeled_AE
63 O
% O
59 O
% O
52 O
% O
48 O
% O
30 O
% O
27 O
% O
26 O
% O
57 O
% O
54 O
% O
48 O
% O
56 O
% O
29 O
% O
22 O
% O
26 O
% O
24 O
% O
29 O
% O
11 O
% O
19 O
% O
17 O
% O
7 O
% O
12 O
% O
22 O
% O
22 O
% O
7 O
% O
22 O
% O
17 O
% O
8 O
% O
14 O
% O
Respiratory B-NonOSE_AE
System I-NonOSE_AE
Pleural B-OSE_Labeled_AE
Effusion I-OSE_Labeled_AE
Dyspnea B-OSE_Labeled_AE
Atelectasis B-OSE_Labeled_AE
30 O
% O
29 O
% O
28 O
% O
32 O
% O
23 O
% O
30 O
% O
36 O
% O
5 O
% O
5 O
% O
35 O
% O
4 O
% O
4 O
% O
Skin B-NonOSE_AE
and I-NonOSE_AE
Appendages I-NonOSE_AE
Pruritus B-OSE_Labeled_AE
Rash B-OSE_Labeled_AE
36 O
% O
24 O
% O
20 O
% O
19 O
% O
15 O
% O
10 O
% O
7 O
% O
4 O
% O
Less O
frequently O
observed O
adverse O
reactions O
in O
both O
liver B-Not_AE_Candidate
transplantation I-Not_AE_Candidate
and O
kidney B-Not_AE_Candidate
transplantation I-Not_AE_Candidate
patients O
are O
described O
under O
the O
subsection O
Less O
Frequently O
Reported O
Adverse O
Reactions O
. O

Heart B-Not_AE_Candidate
Transplantation I-Not_AE_Candidate
The O
incidence O
of O
adverse O
reactions O
was O
determined O
based O
on O
two O
trials O
in O
primary O
orthotopic O
heart B-Not_AE_Candidate
transplantation I-Not_AE_Candidate
. O

In O
a O
trial O
conducted O
in O
Europe O
, O
314 O
patients O
received O
a O
regimen O
of O
antibody O
induction O
, O
corticosteroids O
and O
azathioprine O
( O
AZA O
) O
in O
combination O
with O
Prograf O
( O
n=157 O
) O
or O
cyclosporine O
( O
n=157 O
) O
for O
18 O
months O
. O

The O
trial O
population O
had O
a O
mean O
age O
of O
51 O
years O
( O
range O
18 O
to O
65 O
) O
, O
the O
distribution O
was O
82 O
% O
male O
, O
and O
the O
composition O
was O
White O
( O
96 O
% O
) O
, O
Black O
( O
3 O
% O
) O
and O
other O
( O
1 O
% O
) O
. O

The O
most O
common O
adverse O
reactions O
( O
> O
= O
15 O
% O
) O
observed O
in O
Prograf-treated O
heart B-Not_AE_Candidate
transplant I-Not_AE_Candidate
patients O
are O
: O
abnormal B-OSE_Labeled_AE
renal I-OSE_Labeled_AE
function I-OSE_Labeled_AE
, O
hypertension B-OSE_Labeled_AE
, O
diabetes B-OSE_Labeled_AE
mellitus I-OSE_Labeled_AE
, O
CMV B-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
tremor B-OSE_Labeled_AE
, O
hyperglycemia B-OSE_Labeled_AE
, O
leukopenia B-OSE_Labeled_AE
, O
infection B-OSE_Labeled_AE
, O
anemia B-OSE_Labeled_AE
, O
bronchitis B-OSE_Labeled_AE
, O
pericardial B-OSE_Labeled_AE
effusion I-OSE_Labeled_AE
, O
urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
and O
hyperlipemia B-OSE_Labeled_AE
. O

Adverse O
reactions O
in O
heart B-Not_AE_Candidate
transplant I-Not_AE_Candidate
patients O
in O
the O
European O
trial O
are O
presented O
below O
: O
Table O
8 O
. O

Heart O
Transplantation O
: O
Adverse O
Reactions O
Occurring O
in O
> O
= O
15 O
% O
of O
Patients O
Treated O
with O
Prograf O
in O
Conjunction O
with O
Azathioprine O
( O
AZA O
) O
Prograf/AZA O
( O
n=157 O
) O
Cyclosporine/AZA O
( O
n=157 O
) O
Cardiovascular B-NonOSE_AE
System I-NonOSE_AE
Hypertension B-OSE_Labeled_AE
62 O
% O
69 O
% O
Pericardial B-OSE_Labeled_AE
Effusion I-OSE_Labeled_AE
15 O
% O
14 O
% O
Body B-NonOSE_AE
as I-NonOSE_AE
a I-NonOSE_AE
Whole I-NonOSE_AE
CMV B-OSE_Labeled_AE
Infection I-OSE_Labeled_AE
32 O
% O
30 O
% O
Infection B-OSE_Labeled_AE
24 O
% O
21 O
% O
Metabolic B-NonOSE_AE
and I-NonOSE_AE
Nutritional I-NonOSE_AE
Disorders I-NonOSE_AE
Diabetes B-OSE_Labeled_AE
Mellitus I-OSE_Labeled_AE
26 O
% O
16 O
% O
Hyperglycemia B-OSE_Labeled_AE
23 O
% O
17 O
% O
Hyperlipemia B-OSE_Labeled_AE
18 O
% O
27 O
% O
Hemic B-NonOSE_AE
and I-NonOSE_AE
Lymphatic I-NonOSE_AE
System I-NonOSE_AE
Anemia B-OSE_Labeled_AE
50 O
% O
36 O
% O
Leukopenia B-OSE_Labeled_AE
48 O
% O
39 O
% O
Urogenital B-NonOSE_AE
System I-NonOSE_AE
Kidney B-OSE_Labeled_AE
Function I-OSE_Labeled_AE
Abnormal I-OSE_Labeled_AE
56 O
% O
57 O
% O
Urinary B-OSE_Labeled_AE
Tract I-OSE_Labeled_AE
Infection I-OSE_Labeled_AE
16 O
% O
12 O
% O
Respiratory B-NonOSE_AE
System I-NonOSE_AE
Bronchitis B-OSE_Labeled_AE
17 O
% O
18 O
% O
Nervous B-NonOSE_AE
System I-NonOSE_AE
Tremor B-OSE_Labeled_AE
15 O
% O
6 O
% O
In O
the O
European O
trial O
, O
the O
cyclosporine O
trough O
concentrations O
were O
above O
the O
pre-defined O
target O
range O
( O
i.e. O
, O
100 O
to O
200 O
ng/mL O
) O
at O
Day O
122 O
and O
beyond O
in O
32 O
to O
68 O
% O
of O
the O
patients O
in O
the O
cyclosporine O
treatment O
arm O
, O
whereas O
the O
tacrolimus O
trough O
concentrations O
were O
within O
the O
pre-defined O
target O
range O
( O
i.e. O
, O
5 O
to O
15 O
ng/mL O
) O
in O
74 O
to O
86 O
% O
of O
the O
patients O
in O
the O
tacrolimus O
treatment O
arm O
. O

In O
a O
U.S O
. O
trial O
, O
the O
incidence O
of O
adverse O
reactions O
was O
based O
on O
331 O
heart B-Not_AE_Candidate
transplant I-Not_AE_Candidate
patients O
that O
received O
corticosteroids O
and O
Prograf O
in O
combination O
with O
sirolimus O
( O
n=109 O
) O
, O
Prograf O
in O
combination O
with O
MMF O
( O
n=107 O
) O
or O
cyclosporine O
modified O
in O
combination O
with O
MMF O
( O
n=115 O
) O
for O
1 O
year O
. O

The O
trial O
population O
had O
a O
mean O
age O
of O
53 O
years O
( O
range O
18 O
to O
75 O
) O
, O
the O
distribution O
was O
78 O
% O
male O
, O
and O
the O
composition O
was O
White O
( O
83 O
% O
) O
, O
Black O
( O
13 O
% O
) O
and O
other O
( O
4 O
% O
) O
. O

Only O
selected O
targeted O
treatment-emergent O
adverse O
reactions O
were O
collected O
in O
the O
U.S O
. O
heart B-Not_AE_Candidate
transplantation I-Not_AE_Candidate
trial O
. O

Those O
reactions O
that O
were O
reported O
at O
a O
rate O
of O
15 O
% O
or O
greater O
in O
patients O
treated O
with O
Prograf O
and O
MMF O
include O
the O
following O
: O
any O
target O
adverse O
reactions O
( O
99 O
% O
) O
, O
hypertension B-OSE_Labeled_AE
( O
89 O
% O
) O
, O
hyperglycemia B-OSE_Labeled_AE
requiring O
antihyperglycemic O
therapy O
( O
70 O
% O
) O
, O
hypertriglyceridemia B-OSE_Labeled_AE
( O
65 O
% O
) O
, O
anemia B-OSE_Labeled_AE
( O
hemoglobin B-OSE_Labeled_AE
< I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
. I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
g I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
dL I-OSE_Labeled_AE
) O
( O
65 O
% O
) O
, O
fasting B-OSE_Labeled_AE
blood I-OSE_Labeled_AE
glucose I-OSE_Labeled_AE
> I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
4 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
mg I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
dL I-OSE_Labeled_AE
( O
on O
two O
separate O
occasions O
) O
( O
61 O
% O
) O
, O
hypercholesterolemia B-OSE_Labeled_AE
( O
57 O
% O
) O
, O
hyperlipidemia B-OSE_Labeled_AE
( O
34 O
% O
) O
, O
WBCs B-OSE_Labeled_AE
< I-OSE_Labeled_AE
3 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
cells I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
mcL I-OSE_Labeled_AE
( O
34 O
% O
) O
, O
serious O
bacterial B-OSE_Labeled_AE
infections I-OSE_Labeled_AE
( O
30 O
% O
) O
, O
magnesium B-OSE_Labeled_AE
< I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
. I-OSE_Labeled_AE
2 I-OSE_Labeled_AE
mEq I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
L I-OSE_Labeled_AE
( O
24 O
% O
) O
, O
platelet B-OSE_Labeled_AE
count I-OSE_Labeled_AE
< I-OSE_Labeled_AE
7 I-OSE_Labeled_AE
5 I-OSE_Labeled_AE
, I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
cells I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
mcL I-OSE_Labeled_AE
( O
19 O
% O
) O
, O
and O
other O
opportunistic B-OSE_Labeled_AE
infections I-OSE_Labeled_AE
( O
15 O
% O
) O
. O

Other O
targeted O
treatment-emergent O
adverse O
reactions O
in O
Prograf-treated O
patients O
occurred O
at O
a O
rate O
of O
less O
than O
15 O
% O
, O
and O
include O
the O
following O
: O
Cushingoid B-OSE_Labeled_AE
features I-OSE_Labeled_AE
, O
impaired B-OSE_Labeled_AE
wound I-OSE_Labeled_AE
healing I-OSE_Labeled_AE
, O
hyperkalemia B-OSE_Labeled_AE
, O
Candida B-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
and O
CMV B-OSE_Labeled_AE
infection I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
. O

New O
Onset O
Diabetes O
After O
Transplant O
Kidney O
Transplant O
New B-NonOSE_AE
Onset I-NonOSE_AE
Diabetes I-NonOSE_AE
After I-NonOSE_AE
Transplant I-NonOSE_AE
( I-NonOSE_AE
NODAT I-NonOSE_AE
) O
is O
defined O
as O
a O
composite O
of O
fasting B-NonOSE_AE
plasma I-NonOSE_AE
glucose I-NonOSE_AE
> I-NonOSE_AE
= I-NonOSE_AE
1 I-NonOSE_AE
2 I-NonOSE_AE
6 I-NonOSE_AE
mg I-NonOSE_AE
/ I-NonOSE_AE
dL I-NonOSE_AE
, O
HbA B-NonOSE_AE
1 I-NonOSE_AE
C I-NonOSE_AE
> I-NonOSE_AE
= I-NonOSE_AE
6 I-NonOSE_AE
% I-NonOSE_AE
, O
insulin O
use O
> O
= O
30 O
days O
or O
oral O
hypoglycemic B-NonOSE_AE
use I-NonOSE_AE
. O

In O
a O
trial O
in O
kidney B-Not_AE_Candidate
transplant I-Not_AE_Candidate
patients O
( O
Study O
2 O
) O
, O
NODAT B-OSE_Labeled_AE
was O
observed O
in O
75 O
% O
in O
the O
Prograf-treated O
and O
61 O
% O
in O
the O
Neoral-treated O
patients O
without O
pre-transplant O
history O
of O
diabetes B-Not_AE_Candidate
mellitus I-Not_AE_Candidate
( O
Table O
9 O
) O
[ O
see O
Clinical O
Studies O
( O
14.1 O
) O
] O
. O

Table O
9 O
. O

Incidence O
of O
New O
Onset O
Diabetes O
After O
Transplant O
at O
1 O
year O
in O
Kidney O
Transplant O
Recipients O
in O
a O
Phase O
3 O
Trial O
( O
Study O
2 O
) O
Parameter O
Treatment O
Group O
Prograf/MMF O
( O
n O
= O
212 O
) O
Neoral/MMF O
( O
n O
= O
212 O
) O
NODAT B-OSE_Labeled_AE
112/150 O
( O
75 O
% O
) O
93/152 O
( O
61 O
% O
) O
Fasting B-OSE_Labeled_AE
Plasma I-OSE_Labeled_AE
Glucose I-OSE_Labeled_AE
> I-OSE_Labeled_AE
= I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
2 I-OSE_Labeled_AE
6 I-OSE_Labeled_AE
mg I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
dL I-OSE_Labeled_AE
96/150 O
( O
64 O
% O
) O
80/152 O
( O
53 O
% O
) O
HbA B-OSE_Labeled_AE
1 I-OSE_Labeled_AE
C I-OSE_Labeled_AE
> I-OSE_Labeled_AE
= I-OSE_Labeled_AE
6 I-OSE_Labeled_AE
% I-OSE_Labeled_AE
59/150 O
( O
39 O
% O
) O
28/152 O
( O
18 O
% O
) O
Insulin O
Use O
> O
= O
30 O
days O
9/150 O
( O
6 O
% O
) O
4/152 O
( O
3 O
% O
) O
Oral O
Hypoglycemic B-NonOSE_AE
Use I-NonOSE_AE
15/150 O
( O
10 O
% O
) O
5/152 O
( O
3 O
% O
) O
In O
early O
trials O
of O
Prograf O
, O
Post B-NonOSE_AE
- I-NonOSE_AE
Transplant I-NonOSE_AE
Diabetes I-NonOSE_AE
Mellitus I-NonOSE_AE
( I-NonOSE_AE
PTDM I-NonOSE_AE
) O
was O
evaluated O
with O
a O
more O
limited O
criteria O
of O
`` O
use O
of O
insulin O
for O
30 O
or O
more O
consecutive O
days O
with O
< O
5 O
day O
gap O
'' O
in O
patients O
without O
a O
prior O
history O
of O
insulin B-NonOSE_AE
- I-NonOSE_AE
dependent I-NonOSE_AE
diabetes I-NonOSE_AE
mellitus I-NonOSE_AE
or O
non B-NonOSE_AE
- I-NonOSE_AE
insulin I-NonOSE_AE
dependent I-NonOSE_AE
diabetes I-NonOSE_AE
mellitus I-NonOSE_AE
. O

Data O
are O
presented O
in O
Tables O
10 O
to O
13 O
. O

PTDM B-OSE_Labeled_AE
was O
reported O
in O
20 O
% O
of O
Prograf/Azathioprine O
( O
AZA O
) O
-treated O
kidney B-Not_AE_Candidate
transplant I-Not_AE_Candidate
patients O
without O
pre-transplant O
history O
of O
diabetes B-Not_AE_Candidate
mellitus I-Not_AE_Candidate
in O
a O
Phase O
3 O
trial O
( O
Table O
10 O
) O
. O

The O
median O
time O
to O
onset O
of O
PTDM B-OSE_Labeled_AE
was O
68 O
days O
. O

Insulin O
dependence O
was O
reversible O
in O
15 O
% O
of O
these O
PTDM B-OSE_Labeled_AE
patients O
at O
one O
year O
and O
in O
50 O
% O
at O
2 O
years O
post B-NonOSE_AE
- I-NonOSE_AE
transplant I-NonOSE_AE
. O

Black O
and O
Hispanic O
kidney B-Not_AE_Candidate
transplant I-Not_AE_Candidate
patients O
were O
at O
an O
increased O
risk O
of O
development O
of O
PTDM B-OSE_Labeled_AE
( O
Table O
11 O
) O
. O

Table O
10 O
. O

Incidence O
of O
Post-Transplant O
Diabetes O
Mellitus O
and O
Insulin O
Use O
at O
2 O
Years O
in O
Kidney O
Transplant O
Recipients O
in O
a O
Phase O
3 O
Trial O
using O
Azathioprine O
( O
AZA O
) O
Status O
of O
PTDM B-NonOSE_AE
Use O
of O
insulin O
for O
30 O
or O
more O
consecutive O
days O
, O
with O
< O
5 O
day O
gap O
, O
without O
a O
prior O
history O
of O
insulin B-Not_AE_Candidate
- I-Not_AE_Candidate
dependent I-Not_AE_Candidate
diabetes I-Not_AE_Candidate
mellitus I-Not_AE_Candidate
or O
non B-Not_AE_Candidate
- I-Not_AE_Candidate
insulin I-Not_AE_Candidate
dependent I-Not_AE_Candidate
diabetes I-Not_AE_Candidate
mellitus I-Not_AE_Candidate
. O

Prograf/AZA O
CsA/AZA O
Patients O
without O
pre-transplant O
history O
of O
diabetes B-Not_AE_Candidate
mellitus I-Not_AE_Candidate
151 O
151 O
New O
onset O
PTDM B-OSE_Labeled_AE
, O
1st O
Year O
30/151 O
( O
20 O
% O
) O
6/151 O
( O
4 O
% O
) O
Still O
insulin B-OSE_Labeled_AE
- I-OSE_Labeled_AE
dependent I-OSE_Labeled_AE
at O
one O
year O
in O
those O
without O
prior O
history O
of O
diabetes B-Not_AE_Candidate
25/151 O
( O
17 O
% O
) O
5/151 O
( O
3 O
% O
) O
New O
onset O
PTDM B-OSE_Labeled_AE
post O
1 O
year O
1 O
0 O
Patients O
with O
PTDM B-OSE_Labeled_AE
at O
2 O
years O
16/151 O
( O
11 O
% O
) O
5/151 O
( O
3 O
% O
) O
Table O
11 O
. O

Development O
of O
Post-Transplant O
Diabetes O
Mellitus O
by O
Race O
or O
Ethnicity O
and O
by O
Treatment O
Group O
During O
First O
Year O
Post O
Kidney O
Transplantation O
in O
a O
Phase O
3 O
Trial O
Patient O
Race O
Patients O
Who O
Developed O
PTDM B-NonOSE_AE
Use O
of O
insulin O
for O
30 O
or O
more O
consecutive O
days O
, O
with O
< O
5 O
day O
gap O
, O
without O
a O
prior O
history O
of O
insulin B-Not_AE_Candidate
- I-Not_AE_Candidate
dependent I-Not_AE_Candidate
diabetes I-Not_AE_Candidate
mellitus I-Not_AE_Candidate
or O
non B-Not_AE_Candidate
- I-Not_AE_Candidate
insulin I-Not_AE_Candidate
dependent I-Not_AE_Candidate
diabetes I-Not_AE_Candidate
mellitus I-Not_AE_Candidate
. O

Prograf O
Cyclosporine O
Black O
15/41 O
( O
37 O
% O
) O
3 O
( O
8 O
% O
) O
Hispanic O
5/17 O
( O
29 O
% O
) O
1 O
( O
6 O
% O
) O
Caucasian O
10/82 O
( O
12 O
% O
) O
1 O
( O
1 O
% O
) O
Other O
0/11 O
( O
0 O
% O
) O
1 O
( O
10 O
% O
) O
Total O
30/151 O
( O
20 O
% O
) O
6 O
( O
4 O
% O
) O
Liver O
Transplant O
Insulin B-OSE_Labeled_AE
- I-OSE_Labeled_AE
dependent I-OSE_Labeled_AE
PTDM I-OSE_Labeled_AE
was O
reported O
in O
18 O
% O
and O
11 O
% O
of O
Prograf-treated O
liver B-Not_AE_Candidate
transplant I-Not_AE_Candidate
patients O
and O
was O
reversible O
in O
45 O
% O
and O
31 O
% O
of O
these O
patients O
at O
1 O
year O
post B-NonOSE_AE
- I-NonOSE_AE
transplant I-NonOSE_AE
, O
in O
the O
U.S O
. O
and O
European O
randomized O
trials O
, O
respectively O
, O
( O
Table O
12 O
) O
. O

Hyperglycemia B-OSE_Labeled_AE
was O
associated O
with O
the O
use O
of O
Prograf O
in O
47 O
% O
and O
33 O
% O
of O
liver B-Not_AE_Candidate
transplant I-Not_AE_Candidate
recipients O
in O
the O
U.S O
. O
and O
European O
randomized O
trials O
, O
respectively O
, O
and O
may O
require O
treatment O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

Table O
12 O
. O

Incidence O
of O
Post-Transplant O
Diabetes O
Mellitus O
and O
Insulin O
Use O
at O
1 O
Year O
in O
Liver O
Transplant O
Recipients O
Status O
of O
PTDM B-NonOSE_AE
Use O
of O
insulin O
for O
30 O
or O
more O
consecutive O
days O
, O
with O
< O
5 O
day O
gap O
, O
without O
a O
prior O
history O
of O
insulin B-Not_AE_Candidate
- I-Not_AE_Candidate
dependent I-Not_AE_Candidate
diabetes I-Not_AE_Candidate
mellitus I-Not_AE_Candidate
or O
non B-Not_AE_Candidate
- I-Not_AE_Candidate
insulin I-Not_AE_Candidate
dependent I-Not_AE_Candidate
diabetes I-Not_AE_Candidate
mellitus I-Not_AE_Candidate
. O

US O
Trial O
European O
Trial O
Prograf O
Cyclosporine O
Prograf O
Cyclosporine O
Patients O
at O
riskPatients O
without O
pre-transplant O
history O
of O
diabetes B-Not_AE_Candidate
mellitus I-Not_AE_Candidate
. O

239 O
236 O
239 O
249 O
New O
Onset O
PTDM B-OSE_Labeled_AE
42 O
( O
18 O
% O
) O
30 O
( O
13 O
% O
) O
26 O
( O
11 O
% O
) O
12 O
( O
5 O
% O
) O
Patients O
still O
on O
insulin O
at O
1 O
year O
23 O
( O
10 O
% O
) O
19 O
( O
8 O
% O
) O
18 O
( O
8 O
% O
) O
6 O
( O
2 O
% O
) O
Heart O
Transplant O
Insulin B-OSE_Labeled_AE
- I-OSE_Labeled_AE
dependent I-OSE_Labeled_AE
PTDM I-OSE_Labeled_AE
was O
reported O
in O
13 O
% O
and O
22 O
% O
of O
Prograf-treated O
heart B-Not_AE_Candidate
transplant I-Not_AE_Candidate
patients O
receiving O
mycophenolate O
mofetil O
( O
MMF O
) O
or O
azathioprine O
( O
AZA O
) O
and O
was O
reversible O
in O
30 O
% O
and O
17 O
% O
of O
these O
patients O
at O
one O
year O
post B-NonOSE_AE
- I-NonOSE_AE
transplant I-NonOSE_AE
, O
in O
the O
U.S O
. O
and O
European O
randomized O
trials O
, O
respectively O
( O
Table O
13 O
) O
. O

Hyperglycemia B-OSE_Labeled_AE
defined O
as O
two O
fasting B-OSE_Labeled_AE
plasma I-OSE_Labeled_AE
glucose I-OSE_Labeled_AE
levels I-OSE_Labeled_AE
> I-OSE_Labeled_AE
= I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
2 I-OSE_Labeled_AE
6 I-OSE_Labeled_AE
mg I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
dL I-OSE_Labeled_AE
was O
reported O
with O
the O
use O
of O
Prograf O
plus O
MMF O
or O
AZA O
in O
32 O
% O
and O
35 O
% O
of O
heart B-Not_AE_Candidate
transplant I-Not_AE_Candidate
recipients O
in O
the O
U.S O
. O
and O
European O
randomized O
trials O
, O
respectively O
, O
and O
may O
require O
treatment O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

Table O
13 O
. O

Incidence O
of O
Post-Transplant O
Diabetes O
Mellitus O
and O
Insulin O
Use O
at O
1 O
Year O
in O
Heart O
Transplant O
Recipients O
Status O
of O
PTDM B-NonOSE_AE
Use O
of O
insulin O
for O
30 O
or O
more O
consecutive O
days O
without O
a O
prior O
history O
of O
insulin B-Not_AE_Candidate
- I-Not_AE_Candidate
dependent I-Not_AE_Candidate
diabetes I-Not_AE_Candidate
mellitus I-Not_AE_Candidate
or O
non B-Not_AE_Candidate
- I-Not_AE_Candidate
insulin I-Not_AE_Candidate
dependent I-Not_AE_Candidate
diabetes I-Not_AE_Candidate
mellitus I-Not_AE_Candidate
. O

US O
Trial O
European O
Trial O
Prograf/MMF O
Cyclosporine/MMF O
Prograf/AZA O
Cyclosporine/AZA O
Patients O
at O
riskPatients O
without O
pre-transplant O
history O
of O
diabetes B-Not_AE_Candidate
mellitus I-Not_AE_Candidate
. O

75 O
83 O
132 O
138 O
New O
Onset O
PTDM B-OSE_Labeled_AE
10 O
( O
13 O
% O
) O
6 O
( O
7 O
% O
) O
29 O
( O
22 O
% O
) O
5 O
( O
4 O
% O
) O
Patients O
still O
on O
insulin O
at O
1 O
year O
7-12 O
months O
for O
the O
U.S O
. O
trial O
. O

7 O
( O
9 O
% O
) O
1 O
( O
1 O
% O
) O
24 O
( O
18 O
% O
) O
4 O
( O
3 O
% O
) O
Less O
Frequently O
Reported O
Adverse O
Reactions O
( O
> O
3 O
% O
and O
< O
15 O
% O
) O
The O
following O
adverse O
reactions O
were O
reported O
in O
either O
liver B-Not_AE_Candidate
, O
kidney O
, O
and/or O
heart O
transplant I-Not_AE_Candidate
recipients O
who O
were O
treated O
with O
tacrolimus O
in O
clinical O
trials O
. O

Nervous B-NonOSE_AE
System I-NonOSE_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.8 O
) O
] O
Abnormal B-OSE_Labeled_AE
dreams I-OSE_Labeled_AE
, O
agitation B-OSE_Labeled_AE
, O
amnesia B-OSE_Labeled_AE
, O
anxiety B-OSE_Labeled_AE
, O
confusion B-OSE_Labeled_AE
, O
convulsion B-OSE_Labeled_AE
, O
crying B-OSE_Labeled_AE
, O
depression B-OSE_Labeled_AE
, O
elevated B-OSE_Labeled_AE
mood I-OSE_Labeled_AE
, O
emotional B-OSE_Labeled_AE
lability I-OSE_Labeled_AE
, O
encephalopathy B-OSE_Labeled_AE
, O
haemorrhagic B-OSE_Labeled_AE
stroke I-OSE_Labeled_AE
, O
hallucinations B-OSE_Labeled_AE
, O
hypertonia B-OSE_Labeled_AE
, O
incoordination B-OSE_Labeled_AE
, O
monoparesis B-OSE_Labeled_AE
, O
myoclonus B-OSE_Labeled_AE
, O
nerve B-OSE_Labeled_AE
compression I-OSE_Labeled_AE
, O
nervousness B-OSE_Labeled_AE
, O
neuralgia B-OSE_Labeled_AE
, O
neuropathy B-OSE_Labeled_AE
, O
paralysis B-OSE_Labeled_AE
flaccid I-OSE_Labeled_AE
, O
psychomotor B-OSE_Labeled_AE
skills I-OSE_Labeled_AE
impaired I-OSE_Labeled_AE
, O
psychosis B-OSE_Labeled_AE
, O
quadriparesis B-OSE_Labeled_AE
, O
somnolence B-OSE_Labeled_AE
, O
thinking B-OSE_Labeled_AE
abnormal I-OSE_Labeled_AE
, O
vertigo B-OSE_Labeled_AE
, O
writing B-OSE_Labeled_AE
impaired I-OSE_Labeled_AE
Special B-NonOSE_AE
Senses I-NonOSE_AE
Abnormal B-OSE_Labeled_AE
vision I-OSE_Labeled_AE
, O
amblyopia B-OSE_Labeled_AE
, O
ear B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
otitis B-OSE_Labeled_AE
media I-OSE_Labeled_AE
, O
tinnitus B-OSE_Labeled_AE
Gastrointestinal B-NonOSE_AE
Cholangitis B-OSE_Labeled_AE
, O
cholestatic B-OSE_Labeled_AE
jaundice I-OSE_Labeled_AE
, O
duodenitis B-OSE_Labeled_AE
, O
dysphagia B-OSE_Labeled_AE
, O
esophagitis B-OSE_Labeled_AE
, O
flatulence B-OSE_Labeled_AE
, O
gastritis B-OSE_Labeled_AE
, O
gastroesophagitis B-OSE_Labeled_AE
, O
gastrointestinal B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
, O
GGT B-OSE_Labeled_AE
increase I-OSE_Labeled_AE
, O
GI B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
GI B-OSE_Labeled_AE
perforation I-OSE_Labeled_AE
, O
hepatitis B-OSE_Labeled_AE
, O
hepatitis B-OSE_Labeled_AE
granulomatous I-OSE_Labeled_AE
, O
ileus B-OSE_Labeled_AE
, O
increased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
, O
jaundice B-OSE_Labeled_AE
, O
liver B-OSE_Labeled_AE
damage I-OSE_Labeled_AE
, O
oesophagitis B-OSE_Labeled_AE
ulcerative I-OSE_Labeled_AE
, O
oral B-OSE_Labeled_AE
moniliasis I-OSE_Labeled_AE
, O
pancreatic B-OSE_Labeled_AE
pseudocyst I-OSE_Labeled_AE
, O
rectal B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
stomatitis B-OSE_Labeled_AE
Cardiovascular B-NonOSE_AE
Abnormal B-OSE_Labeled_AE
ECG I-OSE_Labeled_AE
, O
angina B-OSE_Labeled_AE
pectoris I-OSE_Labeled_AE
, O
arrhythmia B-OSE_Labeled_AE
, O
atrial B-OSE_Labeled_AE
fibrillation I-OSE_Labeled_AE
, O
atrial B-OSE_Labeled_AE
flutter I-OSE_Labeled_AE
, O
bradycardia B-OSE_Labeled_AE
, O
cardiac B-OSE_Labeled_AE
fibrillation I-OSE_Labeled_AE
, O
cardiopulmonary B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
cardiovascular B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
congestive B-OSE_Labeled_AE
heart I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
deep B-OSE_Labeled_AE
thrombophlebitis I-OSE_Labeled_AE
, O
echocardiogram B-OSE_Labeled_AE
abnormal I-OSE_Labeled_AE
, O
electrocardiogram B-OSE_Labeled_AE
QRS I-OSE_Labeled_AE
complex I-OSE_Labeled_AE
abnormal I-OSE_Labeled_AE
, O
electrocardiogram B-OSE_Labeled_AE
ST I-OSE_Labeled_AE
segment I-OSE_Labeled_AE
abnormal I-OSE_Labeled_AE
, O
heart B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
heart B-OSE_Labeled_AE
rate I-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
, O
hemorrhage B-OSE_Labeled_AE
, O
hypotension B-OSE_Labeled_AE
, O
peripheral B-OSE_Labeled_AE
vascular I-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
phlebitis B-OSE_Labeled_AE
, O
postural B-OSE_Labeled_AE
hypotension I-OSE_Labeled_AE
, O
syncope B-OSE_Labeled_AE
, O
tachycardia B-OSE_Labeled_AE
, O
thrombosis B-OSE_Labeled_AE
, O
vasodilatation B-OSE_Labeled_AE
Urogenital B-NonOSE_AE
Acute B-OSE_Labeled_AE
kidney I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.7 O
) O
] O
, O
albuminuria B-OSE_Labeled_AE
, O
BK B-OSE_Labeled_AE
nephropathy I-OSE_Labeled_AE
, O
bladder B-OSE_Labeled_AE
spasm I-OSE_Labeled_AE
, O
cystitis B-OSE_Labeled_AE
, O
dysuria B-OSE_Labeled_AE
, O
hematuria B-OSE_Labeled_AE
, O
hydronephrosis B-OSE_Labeled_AE
, O
kidney B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
kidney B-OSE_Labeled_AE
tubular I-OSE_Labeled_AE
necrosis I-OSE_Labeled_AE
, O
nocturia B-OSE_Labeled_AE
, O
pyuria B-OSE_Labeled_AE
, O
toxic B-OSE_Labeled_AE
nephropathy I-OSE_Labeled_AE
, O
urge B-OSE_Labeled_AE
incontinence I-OSE_Labeled_AE
, O
urinary B-OSE_Labeled_AE
frequency I-OSE_Labeled_AE
, O
urinary B-OSE_Labeled_AE
incontinence I-OSE_Labeled_AE
, O
urinary B-OSE_Labeled_AE
retention I-OSE_Labeled_AE
, O
vaginitis B-OSE_Labeled_AE
Metabolic B-NonOSE_AE
/ I-NonOSE_AE
Nutritional I-NonOSE_AE
Acidosis B-OSE_Labeled_AE
, O
alkaline B-OSE_Labeled_AE
phosphatase I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
alkalosis B-OSE_Labeled_AE
, O
ALT B-OSE_Labeled_AE
( I-OSE_Labeled_AE
SGPT I-OSE_Labeled_AE
) I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
AST B-OSE_Labeled_AE
( I-OSE_Labeled_AE
SGOT I-OSE_Labeled_AE
) I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
bicarbonate B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
, O
bilirubinemia B-OSE_Labeled_AE
, O
dehydration B-OSE_Labeled_AE
, O
GGT B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
gout B-OSE_Labeled_AE
, O
healing B-OSE_Labeled_AE
abnormal I-OSE_Labeled_AE
, O
hypercalcemia B-OSE_Labeled_AE
, O
hypercholesterolemia B-OSE_Labeled_AE
, O
hyperphosphatemia B-OSE_Labeled_AE
, O
hyperuricemia B-OSE_Labeled_AE
, O
hypervolemia B-OSE_Labeled_AE
, O
hypocalcemia B-OSE_Labeled_AE
, O
hypoglycemia B-OSE_Labeled_AE
, O
hyponatremia B-OSE_Labeled_AE
, O
hypoproteinemia B-OSE_Labeled_AE
, O
lactic B-OSE_Labeled_AE
dehydrogenase I-OSE_Labeled_AE
increase I-OSE_Labeled_AE
, O
weight B-OSE_Labeled_AE
gain I-OSE_Labeled_AE
Endocrine B-NonOSE_AE
Cushing B-OSE_Labeled_AE
' I-OSE_Labeled_AE
s I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
Hemic B-NonOSE_AE
/ I-NonOSE_AE
Lymphatic I-NonOSE_AE
Coagulation B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
ecchymosis B-OSE_Labeled_AE
, O
haematocrit B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
haemoglobin B-OSE_Labeled_AE
abnormal I-OSE_Labeled_AE
, O
hypochromic B-OSE_Labeled_AE
anemia I-OSE_Labeled_AE
, O
leukocytosis B-OSE_Labeled_AE
, O
polycythemia B-OSE_Labeled_AE
, O
prothrombin B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
, O
serum B-OSE_Labeled_AE
iron I-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
Miscellaneous B-NonOSE_AE
Abdomen B-OSE_Labeled_AE
enlarged I-OSE_Labeled_AE
, O
abscess B-OSE_Labeled_AE
, O
accidental B-OSE_Labeled_AE
injury I-OSE_Labeled_AE
, O
allergic B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
, O
cellulitis B-OSE_Labeled_AE
, O
chills B-OSE_Labeled_AE
, O
fall B-OSE_Labeled_AE
, O
feeling B-OSE_Labeled_AE
abnormal I-OSE_Labeled_AE
, O
flu B-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
generalized B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
, O
hernia B-OSE_Labeled_AE
, O
mobility B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
, O
peritonitis B-OSE_Labeled_AE
, O
photosensitivity B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
, O
sepsis B-OSE_Labeled_AE
, O
temperature B-OSE_Labeled_AE
intolerance I-OSE_Labeled_AE
, O
ulcer B-OSE_Labeled_AE
Musculoskeletal B-NonOSE_AE
Arthralgia B-OSE_Labeled_AE
, O
cramps B-OSE_Labeled_AE
, O
generalized B-OSE_Labeled_AE
spasm I-OSE_Labeled_AE
, O
joint B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
leg B-OSE_Labeled_AE
cramps I-OSE_Labeled_AE
, O
myalgia B-OSE_Labeled_AE
, O
myasthenia B-OSE_Labeled_AE
, O
osteoporosis B-OSE_Labeled_AE
Respiratory B-NonOSE_AE
Asthma B-OSE_Labeled_AE
, O
emphysema B-OSE_Labeled_AE
, O
hiccups B-OSE_Labeled_AE
, O
lung B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
lung B-OSE_Labeled_AE
function I-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
, O
pharyngitis B-OSE_Labeled_AE
, O
pneumonia B-OSE_Labeled_AE
, O
pneumothorax B-OSE_Labeled_AE
, O
pulmonary B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
, O
respiratory B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
rhinitis B-OSE_Labeled_AE
, O
sinusitis B-OSE_Labeled_AE
, O
voice B-OSE_Labeled_AE
alteration I-OSE_Labeled_AE
Skin B-NonOSE_AE
Acne B-OSE_Labeled_AE
, O
alopecia B-OSE_Labeled_AE
, O
exfoliative B-OSE_Labeled_AE
dermatitis I-OSE_Labeled_AE
, O
fungal B-OSE_Labeled_AE
dermatitis I-OSE_Labeled_AE
, O
herpes B-OSE_Labeled_AE
simplex I-OSE_Labeled_AE
, O
herpes B-OSE_Labeled_AE
zoster I-OSE_Labeled_AE
, O
hirsutism B-OSE_Labeled_AE
, O
neoplasm B-OSE_Labeled_AE
skin I-OSE_Labeled_AE
benign I-OSE_Labeled_AE
, O
skin B-OSE_Labeled_AE
discoloration I-OSE_Labeled_AE
, O
skin B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
skin B-OSE_Labeled_AE
ulcer I-OSE_Labeled_AE
, O
sweating B-OSE_Labeled_AE
6.2 O
Postmarketing O
Adverse O
Reactions O
The O
following O
adverse O
reactions O
have O
been O
reported O
from O
worldwide O
marketing O
experience O
with O
Prograf O
. O

Because O
these O
reactions O
are O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
it O
is O
not O
always O
possible O
to O
reliably O
estimate O
their O
frequency O
or O
establish O
a O
causal O
relationship O
to O
drug O
exposure O
. O

Decisions O
to O
include O
these O
reactions O
in O
labeling O
are O
typically O
based O
on O
one O
or O
more O
of O
the O
following O
factors O
: O
( O
1 O
) O
seriousness O
of O
the O
reaction O
, O
( O
2 O
) O
frequency O
of O
the O
reporting O
, O
or O
( O
3 O
) O
strength O
of O
causal O
connection O
to O
the O
drug O
. O

Other O
reactions O
include O
: O
Cardiovascular B-NonOSE_AE
Atrial B-OSE_Labeled_AE
fibrillation I-OSE_Labeled_AE
, O
atrial B-OSE_Labeled_AE
flutter I-OSE_Labeled_AE
, O
cardiac B-OSE_Labeled_AE
arrhythmia I-OSE_Labeled_AE
, O
cardiac B-OSE_Labeled_AE
arrest I-OSE_Labeled_AE
, O
electrocardiogram B-OSE_Labeled_AE
T I-OSE_Labeled_AE
wave I-OSE_Labeled_AE
abnormal I-OSE_Labeled_AE
, O
flushing B-OSE_Labeled_AE
, O
myocardial B-OSE_Labeled_AE
infarction I-OSE_Labeled_AE
, O
myocardial B-OSE_Labeled_AE
ischaemia I-OSE_Labeled_AE
, O
pericardial B-OSE_Labeled_AE
effusion I-OSE_Labeled_AE
, O
QT B-OSE_Labeled_AE
prolongation I-OSE_Labeled_AE
, O
Torsade B-OSE_Labeled_AE
de I-OSE_Labeled_AE
Pointes I-OSE_Labeled_AE
, O
venous B-OSE_Labeled_AE
thrombosis I-OSE_Labeled_AE
deep I-OSE_Labeled_AE
limb I-OSE_Labeled_AE
, O
ventricular B-OSE_Labeled_AE
extrasystoles I-OSE_Labeled_AE
, O
ventricular B-OSE_Labeled_AE
fibrillation I-OSE_Labeled_AE
, O
myocardial B-OSE_Labeled_AE
hypertrophy I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.15 O
) O
] O
. O

Gastrointestinal B-NonOSE_AE
Bile B-OSE_Labeled_AE
duct I-OSE_Labeled_AE
stenosis I-OSE_Labeled_AE
, O
colitis B-OSE_Labeled_AE
, O
enterocolitis B-OSE_Labeled_AE
, O
gastroenteritis B-OSE_Labeled_AE
, O
gastrooesophageal B-OSE_Labeled_AE
reflux I-OSE_Labeled_AE
disease I-OSE_Labeled_AE
, O
hepatic B-OSE_Labeled_AE
cytolysis I-OSE_Labeled_AE
, O
hepatic B-OSE_Labeled_AE
necrosis I-OSE_Labeled_AE
, O
hepatotoxicity B-OSE_Labeled_AE
, O
impaired B-OSE_Labeled_AE
gastric I-OSE_Labeled_AE
emptying I-OSE_Labeled_AE
, O
liver B-OSE_Labeled_AE
fatty I-OSE_Labeled_AE
, O
mouth B-OSE_Labeled_AE
ulceration I-OSE_Labeled_AE
, O
pancreatitis B-OSE_Labeled_AE
haemorrhagic I-OSE_Labeled_AE
, O
pancreatitis B-OSE_Labeled_AE
necrotizing I-OSE_Labeled_AE
, O
stomach B-OSE_Labeled_AE
ulcer I-OSE_Labeled_AE
, O
venoocclusive B-OSE_Labeled_AE
liver I-OSE_Labeled_AE
disease I-OSE_Labeled_AE
Hemic B-NonOSE_AE
/ I-NonOSE_AE
Lymphatic I-NonOSE_AE
Agranulocytosis B-OSE_Labeled_AE
, O
disseminated B-OSE_Labeled_AE
intravascular I-OSE_Labeled_AE
coagulation I-OSE_Labeled_AE
, O
hemolytic B-OSE_Labeled_AE
anemia I-OSE_Labeled_AE
, O
neutropenia B-OSE_Labeled_AE
, O
pancytopenia B-OSE_Labeled_AE
, O
thrombocytopenic B-OSE_Labeled_AE
purpura I-OSE_Labeled_AE
, O
thrombotic B-OSE_Labeled_AE
thrombocytopenic I-OSE_Labeled_AE
purpura I-OSE_Labeled_AE
, O
pure B-OSE_Labeled_AE
red I-OSE_Labeled_AE
cell I-OSE_Labeled_AE
aplasia I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.17 O
) O
] O
Infections B-NonOSE_AE
Cases O
of O
progressive B-OSE_Labeled_AE
multifocal I-OSE_Labeled_AE
leukoencephalopathy I-OSE_Labeled_AE
( I-OSE_Labeled_AE
PML I-OSE_Labeled_AE
) O
, O
sometimes O
fatal B-NonOSE_AE
; O
- O
polyoma B-OSE_Labeled_AE
virus I-OSE_Labeled_AE
- I-OSE_Labeled_AE
associated I-OSE_Labeled_AE
nephropathy I-OSE_Labeled_AE
, I-OSE_Labeled_AE
( I-OSE_Labeled_AE
PVAN I-OSE_Labeled_AE
) O
including O
graft B-OSE_Labeled_AE
loss I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
Metabolic B-NonOSE_AE
/ I-NonOSE_AE
Nutritional I-NonOSE_AE
Glycosuria B-OSE_Labeled_AE
, O
increased B-OSE_Labeled_AE
amylase I-OSE_Labeled_AE
including O
pancreatitis B-OSE_Labeled_AE
, O
weight B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
Miscellaneous B-NonOSE_AE
Feeling B-OSE_Labeled_AE
hot I-OSE_Labeled_AE
and O
cold O
, O
feeling B-OSE_Labeled_AE
jittery I-OSE_Labeled_AE
, O
hot B-OSE_Labeled_AE
flushes I-OSE_Labeled_AE
, O
multi B-OSE_Labeled_AE
- I-OSE_Labeled_AE
organ I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
primary B-OSE_Labeled_AE
graft I-OSE_Labeled_AE
dysfunction I-OSE_Labeled_AE
Nervous B-NonOSE_AE
System I-NonOSE_AE
Carpal B-OSE_Labeled_AE
tunnel I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
cerebral B-OSE_Labeled_AE
infarction I-OSE_Labeled_AE
, O
hemiparesis B-OSE_Labeled_AE
, O
leukoencephalopathy B-OSE_Labeled_AE
, O
mental B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
mutism B-OSE_Labeled_AE
, O
posterior B-OSE_Labeled_AE
reversible I-OSE_Labeled_AE
encephalopathy I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
( I-OSE_Labeled_AE
PRES I-OSE_Labeled_AE
) O
[ O
see O
Warnings O
and O
Precautions O
( O
5.8 O
) O
] O
, O
progressive B-OSE_Labeled_AE
multifocal I-OSE_Labeled_AE
leukoencephalopathy I-OSE_Labeled_AE
( I-OSE_Labeled_AE
PML I-OSE_Labeled_AE
) O
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
, O
quadriplegia B-OSE_Labeled_AE
, O
speech B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
syncope B-OSE_Labeled_AE
Respiratory B-NonOSE_AE
Acute B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
distress I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
interstitial B-OSE_Labeled_AE
lung I-OSE_Labeled_AE
disease I-OSE_Labeled_AE
, O
lung B-OSE_Labeled_AE
infiltration I-OSE_Labeled_AE
, O
respiratory B-OSE_Labeled_AE
distress I-OSE_Labeled_AE
, O
respiratory B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
Skin B-NonOSE_AE
Stevens B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Johnson I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
toxic B-OSE_Labeled_AE
epidermal I-OSE_Labeled_AE
necrolysis I-OSE_Labeled_AE
Special B-NonOSE_AE
Senses I-NonOSE_AE
Blindness B-OSE_Labeled_AE
, O
blindness B-OSE_Labeled_AE
cortical I-OSE_Labeled_AE
, O
hearing B-OSE_Labeled_AE
loss I-OSE_Labeled_AE
including O
deafness B-OSE_Labeled_AE
, O
photophobia B-OSE_Labeled_AE
Urogenital B-NonOSE_AE
Acute B-OSE_Labeled_AE
renal I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
cystitis B-OSE_Labeled_AE
haemorrhagic I-OSE_Labeled_AE
, O
hemolytic B-OSE_Labeled_AE
- I-OSE_Labeled_AE
uremic I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
micturition B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE

